Enzyme Replacement Therapy Medicines
Buyer: The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
- Published
- 15 August 2024
- Estimated value
- £12,437,853
- Place of performance
- UKM
- Procedure
- Direct award
- Lots
- 1
- Notice number
- 025940-2024
- Reference
- ocds-h6vhtk-047915
- Official source
- Official source
CPV codes
- 33600000Pharmaceutical products
Description
Supply of Enzyme Replacement Therapy Medicines (a-d) to NHS Scotland: - NP92624(a) Laronidase 500units/5ml solution for infusion vials 1 vial (Aldurazyme®) - NP92624(b) Imiglucerase 400unit powder for solution for infusion vials 1 vial (Cerezyme®) - NP92624(c) Agalsidase beta 35mg powder for solution for infusion vials 1 vial (Fabrazyme®) - NP92624(c) Agalsidase beta 5mg powder for solution for infusion vials 1 vial (Fabrazyme®) - NP92624(d) Alglucosidase alfa 50mg powder for solution for infusion vials 1 vial (Myozyme®)
Awards
| Awarded to | Amount | Date |
|---|---|---|
| Aventis Pharma Ltd Trading As Sanofi | — | — |
Official publications
- FTS · 025940-2024 · 15 August 2024
Frequently asked questions
- What is the estimated value of this tender?
- The estimated value published by the buyer is £12,437,853.
- Who is the buyer of this tender?
- The contracting authority is The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") (United Kingdom).
- How can I bid for public tenders in the United Kingdom?
- Bids are submitted through the official public procurement portal in the United Kingdom. El Vínculo helps you find tenders and analyse their documents; submission always happens at the official source.
Get alerts for tenders like this
Create a free account and receive new public tenders published in the United Kingdom that match your business, every day.
Create a free account and receive new public tenders published in the United Kingdom that match your business, every day.